

# Public Declaration of Interests and Confidentiality Undertaking of European Medicines Agency (EMA)

## SCIENTIFIC COMMITTEE MEMBERS AND EXPERTS

### I, Maria Judit Molnar

Organisation/Company: N/A

Country: Hungary

Declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

#### 1.1 Employment

No interest declared

#### 1.2 Consultancy

Time Period	Start Date	End Date	Name of pharmaceutical company	Type	Product name	Therapeutic indication	General role / Area of activity
Past	01-10-2018	01-10-2020	Sanofi Genzyme	Cross product related/ general (non product related)	null	null	Advisory board member _ Lysosomal storage disorders
Past	01-05-2019	01-08-2020	PTC Therapeutics	Individual product related	ataluren	Duchenne muscular dystrophy	null
Past	01-01-2017	01-06-2017	Stealth Biotherapeutics	Individual product related	elamipretide	Mitochondrial Myopathy	null
Past	01-03-2018	01-03-2018	Sarepta Therapeutics	Cross product related/ general (non product related)	null	null	Advisory board member _ Duchenne muscular dystrophy
Past	01-06-2015	01-12-2020	Richter Gedeon Plc	Cross product related/ general (non product related)	null	null	Advisory board member _ Expertise in neurology and psychiatry
Past	01-10-2019	01-05-2021	Novartis	Individual product related	Zolgensma (onasemnogene abeparvovec)	SMA	

#### 1.3 Strategic advisory role

No interest declared

#### 1.4 Financial interests

No interest declared

## 1.5 Principal investigator

No interest declared

## 1.6 Investigator

Time Period	Start Date	End Date	Name of pharmaceutical company	Product Name	Therapeutic indication
Current	01-07-2019	22-03-2023	Sarepta	casimersen (SRP_4045)	Duchenne Muscular Dystrophy
Current	01-08-2022	22-03-2023	Stealth Health	elamipretide	Mitochondrial myopathy
Current	01-03-2021	22-03-2023	Chiesi	Lamzedo (velmasa alfa, Alpha Mannosidosi)	Alpha Mannosidosis
Current	01-07-2019		Sarepta	golodirsen (SRP40_53)	Duchenne Muscular Dystrophy
Current	01-05-2022	22-03-2023	Novartis	branaplam	Huntington's disease
Current	01-07-2022	22-03-2023	Sarepta	Eteplirsen	Duchenne Muscular Dystrophy
Past	01-02-2017	01-09-2022	Protalix	pegunigalsidase alfa (PRX 102)	Fabry disease
Past	01-03-2012	01-03-2013	Astellas Pharma	QUTENZA	Painful neuropathy
Past	01-03-2017	01-03-2018	Stealth Health	Pre_Trial Registry	Mitochondrial myopathy
Current	22-08-2022		Sarepta	Eteplirsen (SRP_4051)	Duchenne Muscular Dystrophy
Current	01-12-2022	22-03-2023	Argenix	efgartigimod	Inflammatory myopathies
Current	01-07-2019	22-03-2023	Amicus Therapeutics	cipaglucosidase alfa/miglustat (AT_GAA)	Pompe Disease
Past	01-03-2014	01-02-2015	Novartis	BAF312	Inflammatory myopathy
Past	01-06-2018	01-12-2019	Stealth Biotherapeutics	Elamipretide	Mitochondrial myopathy
Current	01-03-2017	22-03-2023	Minoryx	leroglitazone (MIN_102)	Adrenomyeloneuropathy
Current	01-05-2021	22-03-2023	Argenix	Efgartigimod	Myasthenia gravis
Past	01-05-2019	01-06-2022	Sanofi Genzyme	avalglucosidase	Pompe disease
Past	01-03-2018	01-02-2019	Bristol Mayers	Abatacept	Inflammatory Myopathy
Past	01-03-2015	01-11-2016	Novartis	BAF132	Inflammatory myopathy
Current	01-06-2021	22-03-2023	Reneo Pharmaceuticals	mavodelpar (REN001)	Mitochondrial myopathy

## 1.7 Grant / Funding to organisation /institution

No interest declared

## 1.8 Close family member interest

No interest declared

## 1.9 Repurposing of a medicinal product

No interest declared

## 1.10 Any other interests or facts

The co\_chair of the Scientific Panel of Neuromuscular Disorders of European Academy of Neurology  
The management group member of the Scientific Panel of Neurogenetic Disorders of European Academy of Neurology  
President of the Hungarian Society

of Human Genetics and Genomics The president of the Rare Disease Advisory Board of the Hungarian National Insurance Fund The secretary of the Hungarian Association of Personalized Medicine The member of the Clinical Research Committee of the Medical Research Council in Hungary The member of the management group of the Hungarian College of Clinical Genetic

### 1.11 Committee for Advanced Therapies (CAT) member or alternate

Not a CAT member or alternate

## 2.1 Employment

No interest declared

## 2.2 Consultancy

No interest declared

## 2.3 Strategic advisory role

No interest declared

## 2.4 Financial interests

No interest declared

## 2.5 Principal investigator

No interest declared

## 2.6 Investigator

No interest declared

## 2.7 Grant / Funding to organisation /institution

No interest declared

## 2.8 Close family member interest

No interest declared

## 2.9 Any other interests or facts

No interest declared

---

## CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality as long as the information or document has not been made public/is not in the public domain.

- Not to disclose (or authorise any other person to disclose) in any way to any third party <sup>1</sup> any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.
- When expressing views to indicate clearly that the views are my own if acting in my own capacity or those of the EMA, Management Board, Committee, Working Party, Expert Group or other group if acting on behalf of that group.
- Not to disclose any commercially confidential information.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate and complete to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

*1. Third party does not include employees of the National Competent Authorities who either have employment contracts that provide confidentiality obligations or are encompassed by confidentiality obligations under national legislation on professional secrecy.*

Full Name:	Maria Judit Molnar
Date:	2023-08-27

For definitions of activities etc, refer to the policy on handling of competing interests.